Apps Purchases: 10+ Million Software Purchases
Founded in 2010, APPS RUN THE WORLD is a leading technology intelligence and market-research company devoted to the application space. Leveraging a rigorous data-centric research methodology, we ask the simple B2B sales intelligence question: Who’s buying enterprise applications from whom and why?
Our global team of 50 researchers has been studying the digital transformation initiatives being undertaken by 2 million + companies including technographic segmentation of 10 million ERP, EPM, CRM, HCM, Procurement, SCM, Treasury software purchases, aggregating massive amounts of data points that form the basis of our forecast assumptions and perhaps the rise and fall of certain vendors and their products on a quarterly basis.
Apps Run The World Buyer Insight and Technographics Customer Database has over 100 data fields that detail company usage of emerging technologies such as AI, Machine Learning, IoT, Blockchain, Autonomous Database, and different on-prem and cloud apps by function, customer size (employees, revenues), industry, country, implementation status, year deal won, partner involvement, Line of Business Key Stakeholders and key decision-makers contact details, including the systems being used by Fortune 1000 and Global 2000 companies.
Apply Filters For 10+ Million Software Purchases
- Analytics and BI
| Logo | Customer | Industry | Empl. | Revenue | Country | Vendor | Application | Category | When | VAR/SI | Insight | Insight Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Pfizer | Life Sciences | 81000 | $63.6B | United States | LabWare | LabWare Analytics | Analytics and BI | 2021 | n/a | In 2021, Pfizer implemented LabWare Analytics within its Analytics and BI environment to extend analytics capabilities tied to its LabWare LIMS and ELN platform used across vaccine manufacturing and testing. The deployment emphasized support for U.S. vaccine manufacturing sites and COVID-19 high-throughput testing operations, aligning the application with quality testing and manufacturing workflows at scale. LabWare Analytics was configured to provide advanced data trending and analytics, centralized reporting, and visualization interfaces that surface quality control trends and testing throughput. The implementation emphasized instrumentation of trending workflows and automated data aggregation consistent with Analytics and BI functional patterns, enabling operational teams to interrogate batch and test result trends more rapidly. The implementation integrated LabWare Analytics with LabWare LIMS and ELN data streams to consolidate laboratory results and manufacturing test data into a single analytics layer. Operational coverage focused on quality assurance and manufacturing process control, with data pipelines designed to bring laboratory test results into analytical reports used by site-level and program-level stakeholders. Governance changes formalized use of analytics outputs within QA and manufacturing decision workflows, supporting regulatory compliance and data-driven manufacturing decisions at Pfizer. Outcomes highlighted in vendor descriptions include support for high-throughput testing, improved regulatory compliance evidence, and enabling data-driven manufacturing decisions using LabWare Analytics as the Analytics and BI component for laboratory and manufacturing functions. | |
 |
Oxford Biomedica United Kingdom | Life Sciences | 854 | $161M | United Kingdom | LabVantage Solutions | LabVantage Analytics | Analytics and BI | 2021 | n/a | In October 2021, Oxford Biomedica contracted LabVantage Pharma LIMS as a SaaS solution for its US cell & gene therapy manufacturing site. The case study indicates use of LabVantage Analytics in the Analytics and BI category to support running metrics, dashboards and faster metrics generation, with implementation activities beginning in 2022 and an anticipated go-live in Q2 2024. Deployment is structured as a SaaS LIMS instance centered on the US manufacturing QC operations, configuring QC and sample management workflows to enable batch comparisons and instrumented metrics. Functional capabilities emphasized include QC/sample management, metrics generation for batch comparisons and dashboarding, with workflow automation for sample tracking and reporting aligned to laboratory operations. Governance and rollout are staged across implementation phases starting in 2022, focused on validation and phased go-live planning for the US site in Q2 2024. | |
 |
|
Life Sciences | 200 | $10M | France | LabWare | LabWare Analytics | Analytics and BI | 2022 | n/a |
|
|
|
|
|
Life Sciences | 78554 | $45.9B | Denmark | Qlik | Qlik Sense | Analytics and BI | 2014 | n/a |
|
|
|
|
|
Life Sciences | 54500 | $28.9B | Germany | Lifebit | Lifebit | Analytics and BI | 2022 | n/a |
|
|
|
|
|
Life Sciences | 111408 | $75.7B | Germany | Lokalise | Lokalise Analytics | Analytics and BI | 2016 | n/a |
|
|
|
|
|
Life Sciences | 300 | $40M | China | Microsoft | Azure Text Analytics | Analytics and BI | 2022 | Microsoft |
|
|
|
|
|
Life Sciences | 71400 | $23.5B | Germany | Microsoft | Microsoft Azure Anomaly Detector i | Analytics and BI | 2021 | n/a |
|
|
|
|
|
Life Sciences | 75883 | $51.7B | Switzerland | Model N | Model N Intelligence Cloud | Analytics and BI | 2019 | n/a |
|
|
|
|
|
Life Sciences | 10 | $1M | United States | Umami | Umami | Analytics and BI | 2024 | n/a |
|
|